Moberg Pharma announces grant of EU Patent for MOB-015 related to topical treatment of onychomycosis (nail fungus)

STOCKHOLM, March 26, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that
the European Patent Office has issued Patent no. 2 672 962, relating to its
topical treatment MOB-015 for onychomycosis (nail fungus). The patent is
expected to be in effect until 2032.  In September 2014, Moberg Pharma reported
positive results from a Phase II study of MOB-015 and in January 2015, received
similar patent approval in the U.S.
The new EU patent comprises composition of matter claims directed to novel
topical formulations of antifungal allylamines (including terbinafine), as well
as claims directed to methods of treatment of onychomycosis using these novel
formulations, which enable enhanced penetration of antifungal allylamines into
and through the nail. Moberg Pharma is pursuing corresponding patent approval in
all major territories.

"The granted European patent in addition to the recently approved U.S. patent
strengthens the value of our MOB-015 asset. We continue to progress discussions
with potential partners and are preparing for start of phase III in 2016,” said
Peter Wolpert, CEO of Moberg Pharma AB.

Mr. Wolpert added: “The rapid growth of the value of the U.S. Rx onychomycosis
market during the last 9 months further strengthens the attractiveness of the
indication. Based on the phase II results, MOB-015 has the potential to become
superior to other topical treatments, including the recently launched products.”

About MOB-015 and Onychomycosis
Approximately 10% of the general population suffer from onychomycosis and a
majority of those afflicted go untreated. The prescription market is growing
rapidly after the recent introduction of new topical treatments in North America
and Japan. Moberg Pharma expects the U.S. market alone to exceed $2 billion by
2020 and estimates the peak sales potential for MOB-015 to be in the range of
$250-$500 million.

MOB-015 is an internally developed topical formulation of terbinafine building
on Moberg Pharma’s experience from the OTC market. Oral terbinafine is the gold
standard for treating onychomycosis, but associated with safety issues including
drug interactions and liver injury. Prior to MOB-015, developing a topical
terbinafine treatment without the safety issues of oral terbinafine has been
highly desirable, but unsuccessful due to insufficient delivery of the active
substance through the nail.

In a recent Phase II study, MOB-015 demonstrated delivery of high microgram
levels of terbinafine into the nail, as well as through the nail plate into the
nail bed. Mycological cure of 54% and significant clear nail growth was observed
in patients who completed the recent phase II study. The results are remarkable,
particularly when taking into account that the majority of the patients treated
had severely affected nails – on average approximately 60% of the nail plate was
affected by the infection.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 a.m. (CET) on March 26, 2015.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135, E-mail:
peter.wolpert@mobergpharma.se
Kjell Rensfeldt, VP R&D, Telephone: +46 (0)70 – 712 4532, E-mail:
kjell.rensfeldt@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Jointflex®,
Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Emtrix® or
Nalox™ in certain ex-U.S. markets) is a leading OTC treatment of nail disorders
in the U.S., Canada and several EU markets and is currently being launched in
Southeast Asia. The company is growing organically as well as through
acquisitions. Internal development programs focuses on innovative drug delivery
of proven compounds and include two phase II assets, MOB-015 (onychomycosis) and
BUPI (oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and
the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ
OMX Nordic Exchange Stockholm. For further information, please visit:
www.mobergpharma.com.